🚀 VC round data is live in beta, check it out!
OrthoPediatrics Valuation Multiples
Discover revenue and EBITDA valuation multiples for OrthoPediatrics and similar public comparables like CellaVision, IVF hartmann, Coltene, Cerus and more.
OrthoPediatrics Overview
About OrthoPediatrics
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
Founded
2007
HQ
Employees
562
Website
Financials (LTM)
EV
$462M
OrthoPediatrics Financials
OrthoPediatrics reported last 12-month revenue of $245M and EBITDA of $18M.
In the same LTM period, OrthoPediatrics generated $179M in gross profit, $18M in EBITDA, and had net loss of ($36M).
Revenue (LTM)
OrthoPediatrics P&L
In the most recent fiscal year, OrthoPediatrics reported revenue of $236M and EBITDA of $15M.
OrthoPediatrics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $245M | XXX | $236M | XXX | XXX | XXX |
| Gross Profit | $179M | XXX | $173M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $18M | XXX | $15M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | (14%) | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | ($36M) | XXX | ($40M) | XXX | XXX | XXX |
| Net Margin | (15%) | XXX | (17%) | XXX | XXX | XXX |
| Net Debt | — | — | $80M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
OrthoPediatrics Stock Performance
OrthoPediatrics has current market cap of $423M, and enterprise value of $462M.
Market Cap Evolution
OrthoPediatrics' stock price is $16.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $462M | $423M | 0.0% | XXX | XXX | XXX | $-1.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrthoPediatrics Valuation Multiples
OrthoPediatrics trades at 1.9x EV/Revenue multiple, and 26.0x EV/EBITDA.
EV / Revenue (LTM)
OrthoPediatrics Financial Valuation Multiples
As of April 20, 2026, OrthoPediatrics has market cap of $423M and EV of $462M.
Equity research analysts estimate OrthoPediatrics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OrthoPediatrics has a P/E ratio of (11.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $423M | XXX | $423M | XXX | XXX | XXX |
| EV (current) | $462M | XXX | $462M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 26.0x | XXX | 31.3x | XXX | XXX | XXX |
| EV/EBIT | (13.7x) | XXX | (15.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.7x | XXX | XXX | XXX |
| P/E | (11.8x) | XXX | (10.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (29.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified OrthoPediatrics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
OrthoPediatrics Margins & Growth Rates
OrthoPediatrics' revenue in the last 12 month grew by 12%.
OrthoPediatrics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
OrthoPediatrics' rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OrthoPediatrics' rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
OrthoPediatrics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 59% | XXX | 69% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 30% | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 50% | XXX | 51% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
OrthoPediatrics Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OrthoPediatrics | XXX | XXX | XXX | XXX | XXX | XXX |
| CellaVision | XXX | XXX | XXX | XXX | XXX | XXX |
| IVF hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| Coltene | XXX | XXX | XXX | XXX | XXX | XXX |
| Cerus | XXX | XXX | XXX | XXX | XXX | XXX |
| AngioDynamics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OrthoPediatrics M&A Activity
OrthoPediatrics acquired XXX companies to date.
Last acquisition by OrthoPediatrics was on XXXXXXXX, XXXXX. OrthoPediatrics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by OrthoPediatrics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOrthoPediatrics Investment Activity
OrthoPediatrics invested in XXX companies to date.
OrthoPediatrics made its latest investment on XXXXXXXX, XXXXX. OrthoPediatrics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by OrthoPediatrics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout OrthoPediatrics
| When was OrthoPediatrics founded? | OrthoPediatrics was founded in 2007. |
| Where is OrthoPediatrics headquartered? | OrthoPediatrics is headquartered in United States. |
| How many employees does OrthoPediatrics have? | As of today, OrthoPediatrics has over 562 employees. |
| Who is the CEO of OrthoPediatrics? | OrthoPediatrics' CEO is David R. Bailey. |
| Is OrthoPediatrics publicly listed? | Yes, OrthoPediatrics is a public company listed on Nasdaq. |
| What is the stock symbol of OrthoPediatrics? | OrthoPediatrics trades under KIDS ticker. |
| When did OrthoPediatrics go public? | OrthoPediatrics went public in 2017. |
| Who are competitors of OrthoPediatrics? | OrthoPediatrics main competitors are CellaVision, IVF hartmann, Coltene, Cerus. |
| What is the current market cap of OrthoPediatrics? | OrthoPediatrics' current market cap is $423M. |
| What is the current revenue of OrthoPediatrics? | OrthoPediatrics' last 12 months revenue is $245M. |
| What is the current revenue growth of OrthoPediatrics? | OrthoPediatrics revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of OrthoPediatrics? | Current revenue multiple of OrthoPediatrics is 1.9x. |
| Is OrthoPediatrics profitable? | Yes, OrthoPediatrics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OrthoPediatrics? | OrthoPediatrics' last 12 months EBITDA is $18M. |
| What is OrthoPediatrics' EBITDA margin? | OrthoPediatrics' last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of OrthoPediatrics? | Current EBITDA multiple of OrthoPediatrics is 26.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.